REFERENCES
- Badros A, Goloubeva O, Terpos E, et al. Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br J Haematol 2008;142:492–494.
- Ng AC, Kumar SK, Rajkumar SV, Drake MT. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. Am J Haematol 2009;84:397–400
- Clement Z, Sivakumaran S. Vitamin D deficiency in a man with multiple myeloma. North Am J Med Sci 2011;3: 469–471.
- Bischoff-Ferrari HA. Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol. 2008;624: 55–71.
- Gupta D, Vashi P, Trukova K, Lis C, Lammersfeld C. Prevalence of serum vitamin D deficiency and insufficiency in cancer: Review of the epidemiological literature. Exp Ther Med 2011;2(2): 181–193.
- Porter A, Gilmartin C, Srisakul U, Arruda J, Akkina S. Prevalence of 25-OH vitamin d deficiency in a population of hemodialysis patients and efficacy of an oral ergocalciferol supplementation regimen. Am J Nephrol 2013;37(6):568–574.
- Chatfield SM, Brand C, Ebeling PR, Russell DM. Vitamin D deficiency in general medical inpatients in summer and winter. Intern Med J 2007;37:377–382.
- Mohr SB, Gorham ED, Grant WB, Garland FC, Cuomo RE. Are low ultraviolet B and vitamin D associated with higher incidence of multiple myeloma? J. Steroid Biochem. Mol. Biol. 2014; 148:242–252. doi:10.1016/j.jsbmb.2014.12.005
- Williams S, Malatesta K, Norris Keith. Vitamin D and chronic kidney disease. Ethn Dis. 2009;19(4 Suppl 5):S5–8–11.
- Ozdemir F, Esen N, Ovali E, Tekelioglu Y, Yilmaz M, Aydin F. et al. Effects of dexamethasone, all-trans retinoic acid, vitamin D (3) and interferon-alpha on FO myeloma cells. Chemotherapy 2004;50(4):190–193.
- Kumagai T, O'Kelly J, Said JW, Koeffler HP. Vitamin D2 analog 19-nor-1, 25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. J Natl Cancer Inst 2003;95(12):896–905.
- Schmeel LC, Schmeel FC, Kim Y, Endo T, LU D, Schmidt-Wolf IG. Targeting the Wnt/beta-catenin pathway in multiple myeloma. Anticancer Res 2013;33(11):4719–4726.
- Yordanova A, Hose D, Neben K, Witzens-Harig M, Gütgemann I, Raab MS, et al. Sorafenib in patients with refractory or recurrent multiple myeloma. Hematol Oncol 2013;31(4):197–200. doi:10.1002/hon2043.Epub2013 Mar 15.
- Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012 Aug 20;30(24):2946–55. doi:10.1200/JCO.2011.39.6820. Epub 2012 Jul 16.
- Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, Bertsch U, et al. Dutch-Belgian HOVON; German GMMG. Thalidomid in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008;93(1):124–7 103324/haematol.11644